NATIONAL CANCER NETWORK TO GUIDE DRUG COVERAGE CHOICES

Published Online: Tuesday, July 1, 2008

The Centers for Medicare & Medicaid Services (CMS) has recognized the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium as a mandated reference for making coverage decisions on the use of drugs and biologics in cancer care.

The NCCN compendium will be used by CMS for its national coverage determinations and by intermediaries and carriers for their regional determinations. One important application will be guiding decisions about coverage for the use of drugs and biologics in oncology beyond the FDA-approved indication.

The NCCN is an alliance of 21 of the world?s leading cancer centers dedicated to promoting high-quality cancer care; its clinical oncology practice guidelines are used widely by patients, clinicians, and other health care decision makers.



Latest Articles
This weekly video program provides our readers with an in-depth review of the latest news, product approvals, FDA rulings and more.
Chronic kidney disease incidence has grown faster than many of its common comorbidities such as diabetes and hypertension, and medications may be an underappreciated driver of this growth.
President Barack Obama’s fiscal year 2017 budget proposal calls for an additional $1.1 billion to combat the nation’s spiraling opioid epidemic.
Baxter International is voluntarily recalling intravenous solution due to leaking containers and the potential for particulate matter.
Latest Issues
$auto_registration$
VSEO N/A